| Comparison of in vitro and in vivo biological effects of trabectedin, lurbinectedin (PM01183) and Zalypsis® (PM00104) M Romano, R Frapolli, M Zangarini, E Bello, L Porcu, CM Galmarini, ... International journal of cancer 133 (9), 2024-2033, 2013 | 70 | 2013 |
| Pharmacokinetics and antineoplastic activity of galectin-1-targeting OTX008 in combination with sunitinib M Zucchetti, K Bonezzi, R Frapolli, F Sala, P Borsotti, M Zangarini, ... Cancer chemotherapy and pharmacology 72, 879-887, 2013 | 40 | 2013 |
| In vitro and in vivo activity of lucitanib in FGFR1/2 amplified or mutated cancer models F Guffanti, R Chilà, E Bello, M Zucchetti, M Zangarini, L Ceriani, M Ferrari, ... Neoplasia 19 (1), 35-42, 2017 | 24 | 2017 |
| Targeting tropomyosin receptor kinase in cutaneous CYLD defective tumors with pegcantratinib: the TRAC randomized clinical trial M Danilenko, E Stamp, DD Stocken, A Husain, M Zangarini, A Cranston, ... JAMA dermatology 154 (8), 913-921, 2018 | 18 | 2018 |
| Evaluation of levothyroxine bioavailability after oral administration of a fixed combination of soy isoflavones in post-menopausal female volunteers S Persiani, F Sala, C Manzotti, M Colovic, M Zangarini, Y Donazzolo, ... Drug Research 66 (03), 136-140, 2016 | 15 | 2016 |
| Quantification of trabectedin in human plasma: Validation of a high-performance liquid chromatography–mass spectrometry method and its application in a clinical pharmacokinetic … M Zangarini, L Ceriani, F Sala, E Marangon, R Bagnati, M D’Incalci, ... Journal of Pharmaceutical and Biomedical Analysis 95, 107-112, 2014 | 13 | 2014 |
| Phase Ib of sorafenib in combination with everolimus in patients with advanced solid tumors, selected on the basis of molecular targets F Toffalorio, G Spitaleri, C Catania, L Dal Zotto, C Noberasco, A Delmonte, ... The Oncologist 19 (4), 344-345, 2014 | 10 | 2014 |
| Development and validation of a LC–MS/MS method for the quantification of the checkpoint kinase 1 inhibitor SRA737 in human plasma M Zangarini, P Berry, J Sludden, FI Raynaud, U Banerji, P Jones, ... Bioanalysis 9 (13), 1001-1010, 2017 | 9 | 2017 |
| HPLC–MS/MS method to measure trabectedin in tumors: Preliminary PK study in a mesothelioma xenograft model L Ceriani, M Ferrari, M Zangarini, SA Licandro, E Bello, R Frapolli, ... Bioanalysis 7 (15), 1831-1842, 2015 | 9 | 2015 |
| Testing ATRA and MEK inhibitor PD0325901 effectiveness in a nude mouse model for human MPNST xenografts S Fischer-Huchzermeyer, L Chikobava, V Stahn, M Zangarini, P Berry, ... BMC Research Notes 11, 1-7, 2018 | 5 | 2018 |
| Effect of food on the oral bioavailability of berberine and monacolin administered in combination in healthy male volunteers S Persiani, F Sala, M Zangarini, C Manzotti, M Colovic, Y Donazzolo, ... J Pharm Pharmacol 2 (703), e12, 2014 | 5 | 2014 |
| HPLC‐MS/MS method for quantitative determination of the novel dual inhibitor of FGF and VEGF receptors E‐3810 in tumor tissues from xenograft mice and human biopsies M Zangarini, L Ceriani, E Bello, G Damia, R Cereda, MG Camboni, ... Journal of Mass Spectrometry 49 (1), 19-26, 2014 | 4 | 2014 |
| Development and validation of LC–MS/MS with in-source collision-induced dissociation for the quantification of pegcantratinib in human skin tumors M Zangarini, N Rajan, M Danilenko, P Berry, S Traversa, GJ Veal Bioanalysis 9 (3), 279-288, 2017 | 3 | 2017 |
| 340 Preclinical activity of the VEGFR, FGFR and PDGFR inhibitor lucitanib in FGFR2 aberrant endometrial and gastric cancer models F Guffanti, R Chila, E Bello, L Ceriani, M Zangarini, M Zucchetti, C Saba, ... European Journal of Cancer, 110, 2014 | 3 | 2014 |
| Pharmacokinetics of the Novel FGFR and VEGFR Inhibitor, E-3810, in Patients with Advanced Solid Tumors Participating to a Phase I/II Trial M Zangarini, F Sala, MG Camboni, R Cereda, V Livi, R Bahleda, ... European Journal of Cancer 48, 183-183, 2012 | 3 | 2012 |
| Diverse assays from a single skin punch biopsy to assess topical drug intervention M Danilenko, K Hodgson, R Stones, A Husain, M Zangarini, G Veal, ... British Journal of Dermatology 180 (4), 937-938, 2019 | 1 | 2019 |
| Exploring the in vitro and in vivo activity of lucitanib in FGFR1-amplified lung cancer models E Bello, R Chilà, F Guffanti, M Zangarini, L Ceriani, M Zucchetti, S Chaudi, ... Cancer Research 74 (19_Supplement), 2670-2670, 2014 | 1 | 2014 |
| Targeting tropomyosin receptor kinase in cutaneous CYLD defective tumors (TRAC): A randomised placebo-controlled early phase trial with pegcantratinib M Danilenko, E Stamp, DD Stocken, A Husain, M Zangarini, A Cranston, ... JAMA Dermatology, 2018 | | 2018 |
| Development and validation of a LC-MS/MS method for the quantification of the tropomyosin receptor kinase (Trk) inhibitor pegcantratinib in human skin tumors M Zangarini, N Rajan, M Danilenko, P Berry, GJ Veal Cancer Research 76 (14_Supplement), 333-333, 2016 | | 2016 |
| Evaluation of the tumor activity and pharmacokinetic profile of PM01183, a novel alkaloid of marine origin M Zangarini, R Frapolli, E Bello, M Zucchetti, M D'Incalci SPSAS São Paulo School of Advanced Sciences, São Paulo (Brazil) 68 (A57), 2013 | | 2013 |
damia giovannaChief, DNA repair unit, Mario negri instituteVerified email at marionegri.it
